Study of DJ meson decays to D+π−, D0π+ and D∗+π− final states in pp collisions

A study of D+π−, D0π+ and D∗+π− final states is performed using pp collision data, corresponding to an integrated luminosity of 1.0 fb−1, collected at a centre-of-mass energy of 7 TeV with the LHCb detector. The D1(2420)0 resonance is observed in the D∗+π− final state and the D∗2(2460) resonance is observed in the D+π−, D0π+ and D∗+π− final states. For both resonances, their properties and spin-parity assignments are obtained. In addition, two natural parity and two unnatural parity resonances are observed in the mass region between 2500 and 2800 MeV. Further structures in the region around 3000 MeV are observed in all the D∗+π−, D+π− and D0π+ final states

Measurement of the Bs0→J/ψK∗0B^0_s\rightarrow J/\psi K^{*0} branching fraction and angular amplitudes

A search for the decay $B^0_s\rightarrow J/\psi K^{*0}$ with $K^{*0} \rightarrow K^-\pi^+$ is performed with 0.37 fb$^{-1}$ of $pp$ collisions at $\sqrt{s}$ = 7 TeV collected by the LHCb experiment, finding a \Bs \to J\psi K^-\pi^+ peak of $114 \pm 11$ signal events. The $K^-\pi^+$ mass spectrum of the candidates in the $B^0_s$ peak is dominated by the $K^{*0}$ contribution. Subtracting the non-resonant $K^-\pi^+$ component, the branching fraction of \BsJpsiKst is $(4.4_{-0.4}^{+0.5} \pm 0.8) \times 10^{-5}$, where the first uncertainty is statistical and the second systematic. A fit to the angular distribution of the decay products yields the \Kst polarization fractions $f_L = 0.50 \pm 0.08 \pm 0.02$ and $f_{||} = 0.19^{+0.10}_{-0.08} \pm 0.02$

Measurements of the differential jet cross section as a function of the jet mass in dijet events from proton-proton collisions at √s=13 TeV

Measurements of the differential jet cross section are presented as a function of the jet mass in dijet events, in bins of jet transverse momentum, with and without a jet grooming algorithm. The data have been recorded by the CMS Collaboration in proton-proton collisions at the LHC at a center-of-mass energy of 13 TeV and correspond to an integrated luminosity of 2.3 fb−1. The absolute cross sections show slightly different jet transverse momentum spectra in data and Monte Carlo event generators for the settings used. Removing this transverse momentum dependence, the normalized cross section for ungroomed jets is consistent with the prediction from Monte Carlo event generators for masses below 30% of the transverse momentum. The normalized cross section for groomed jets is measured with higher precision than the ungroomed cross section. Semi-analytical calculations of the jet mass beyond leading logarithmic accuracy are compared to data, as well as predictions at leading order and next-to-leading order, which include parton showering and hadronization. Overall, in the normalized cross section, the theoretical predictions agree with the measured cross sections within the uncertainties for masses from 10 to 30% of the jet transverse momentum

Combined measurements of Higgs boson couplings in proton- proton collisions at v s=13TeV

Combined measurements of the production and decay rates of the Higgs boson, as well as its couplings to vector bosons and fermions, are presented. The analysis uses the LHC proton-proton collision data set recorded with the CMS detector in 2016 at fb-1. The combination is based on analyses targeting the five main Higgs boson production mechanisms (gluon fusion, vector boson fusion, and associated production with a W or Z boson, or a top quark-antiquark pair) and the following decay modes: H, ZZ, WW, , bb, and . Searches for invisible Higgs boson decays are also considered. The best-fit ratio of the signal yield to the standard model expectation is measured to be =1.17 +/- 0.10, assuming a Higgs boson mass of 125.09. Additional results are given for various assumptions on the scaling behavior of the production and decay modes, including generic parametrizations based on ratios of cross sections and branching fractions or couplings. The results are compatible with the standard model predictions in all parametrizations considered. In addition, constraints are placed on various two Higgs doublet models.Peer reviewe

Measurement of prompt D-0 and D-0 meson azimuthal anisotropy and search for strong electric fields in PbPb collisions at root S-NN=5.02 TeV

SCOAP

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049